2000
DOI: 10.1002/(sici)1097-0290(19960305)49:5<578::aid-bit11>3.0.co;2-6
|View full text |Cite
|
Sign up to set email alerts
|

Continuous culture study of the expression of hepatitis B surface antigen and its self-assembly into virus-like particles in Saccharomyces cerevisiae

Abstract: We have studied the growth rate dependence of hepatitis B surface antigen (HBsAg) p24s monomer and lipoprotein particle synthesis produced in Saccharomyces cerevisiae using galactose‐limited continuous culture. The hepatitis B virus S gene, which encodes the p24s monomer, is transcribed under the control of the GAL 10p on a chimeric 2‐μm plasmid harbored in a haploid yeast strain. Monomers autonomously form lipoprotein aggregates (particles) in vivo using only host‐cell‐derived components. Steady states were e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2002
2002
2016
2016

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(6 citation statements)
references
References 33 publications
0
6
0
Order By: Relevance
“…In contrast, the hepatitis B vaccine lacks the ability to induce durable antibody titres, even after a prime-boost-boost regimen and protection seems, in this case, to depend on memory B cells rather than on long-lived plasma cells [14, 29, 30]. The HBV vaccine is composed of the HBsAg, presented, at low density (100–120 HBsAg per VLP), on the surface of non-rigid lipid particles [31, 32], and it has been proposed that HBV particles represent a sub-optimal virus-like epitope display compared to HPV L1 VLPs [33]. Accordingly, since it appears that the RTS,S vaccine is protective only while antibodies are circulating, HBsAg VLPs (i.e., the hepatitis B vaccine) are likely a sub-optimal platform for displaying the CSP antigen.…”
Section: Discussionmentioning
confidence: 99%
“…In contrast, the hepatitis B vaccine lacks the ability to induce durable antibody titres, even after a prime-boost-boost regimen and protection seems, in this case, to depend on memory B cells rather than on long-lived plasma cells [14, 29, 30]. The HBV vaccine is composed of the HBsAg, presented, at low density (100–120 HBsAg per VLP), on the surface of non-rigid lipid particles [31, 32], and it has been proposed that HBV particles represent a sub-optimal virus-like epitope display compared to HPV L1 VLPs [33]. Accordingly, since it appears that the RTS,S vaccine is protective only while antibodies are circulating, HBsAg VLPs (i.e., the hepatitis B vaccine) are likely a sub-optimal platform for displaying the CSP antigen.…”
Section: Discussionmentioning
confidence: 99%
“…An unbaffled 250 mL Erlenmeyer shake flask culture was prepared with a chemically defined medium (Fu et al, 1995) with 4% dextrose and 1% (v/v) inoculum from a thawed S. cerevisiae ISB seed stock. The cultures were incubated for approximately 24 h at 28-C, 250 rpm.…”
Section: Data Acquisition Systemmentioning
confidence: 99%
“…The hepatitis vaccine is composed of a VLP based on the hepatitis B surface antigen (HBsAg). It can be produced recombinantly in yeast, such as Saccharomyces cerevisiae [17][18][19][20][21] or mammalian cells [22]. It buds from the endoplasmic reticulum as a 22 nm lipoprotein ( Fig.…”
Section: Introductionmentioning
confidence: 99%